inclusion criteria: 1. adult male or female ≥18 to ≤80 years of age 2. proven covid-19 infection per rt-pcr assay of a pharyngeal sample (nasopharyngeal or oropharyngeal) and pneumonia defined as radiographic opacities on chest x-ray or ct scan. that diagnosed covid-19 pneumonia. pharyngeal samples collected either at screening or within 7-days prior to screening for the same ongoing covid-19 pneumonia illness are acceptable 3. the patient requires, at baseline, high flow supplemental oxygen or positive pressure ventilation or is receiving oxygen via face mask, such as a non-rebreather or reservoir mask, capable of delivering high concentrations of oxygen 4. patient agrees to use appropriate methods of contraception during the study and 3 months after the last dose of study drug 5. the patient or legal representative has signed a written informed consent approved by the irb/ethics committee

inclusion criteria: 1. adult male or female ≥18 to ≤80 years of age 2. proven covid-19 infection per rt-pcr assay of a pharyngeal sample (nasopharyngeal or oropharyngeal) and pneumonia defined as radiographic opacities on chest x-ray or ct scan. that diagnosed covid-19 pneumonia. pharyngeal samples collected either at screening or within 7-days prior to screening for the same ongoing covid-19 pneumonia illness are acceptable 3. the patient requires, at baseline, high flow supplemental oxygen or positive pressure ventilation or is receiving oxygen via face mask, such as a non-rebreather or reservoir mask, capable of delivering high concentrations of oxygen 4. patient agrees to use appropriate methods of contraception during the study and 3 months after the last dose of study drug 5. the patient or legal representative has signed a written informed consent approved by the irb/ethics committee

inclusion criteria: adult male or female ≥18 to ≤80 years of age proven covid-19 infection per rt-pcr assay of a pharyngeal sample (nasopharyngeal or oropharyngeal) and pneumonia defined as radiographic opacities on chest x-ray or ct scan. that diagnosed covid-19 pneumonia. pharyngeal samples collected either at screening or within 7-days prior to screening for the same ongoing covid-19 pneumonia illness are acceptable the patient requires, at baseline, high flow supplemental oxygen or positive pressure ventilation or is receiving oxygen via face mask, such as a non-rebreather or reservoir mask, capable of delivering high concentrations of oxygen patient agrees to use appropriate methods of contraception during the study and 3 months after the last dose of study drug the patient or legal representative has signed a written informed consent approved by the irb/ethics committee

inclusion criteria: adult male or female ≥18 to ≤80 years of age proven covid-19 infection per rt-pcr assay of a pharyngeal sample (nasopharyngeal or oropharyngeal) and pneumonia defined as radiographic opacities on chest x-ray or ct scan. that diagnosed covid-19 pneumonia. pharyngeal samples collected either at screening or within 7-days prior to screening for the same ongoing covid-19 pneumonia illness are acceptable the patient requires, at baseline, high flow supplemental oxygen or positive pressure ventilation or is receiving oxygen via face mask, such as a non-rebreather or reservoir mask, capable of delivering high concentrations of oxygen patient agrees to use appropriate methods of contraception during the study and 3 months after the last dose of study drug the patient or legal representative has signed a written informed consent approved by the irb/ethics committee

inclusion criteria: 1. adult male or female ≥18 to ≤80 years of age 2. proven covid-19 infection per rt-pcr assay of a pharyngeal sample (nasopharyngeal or oropharyngeal) and pneumonia defined as radiographic opacities on chest x-ray or ct scan. that diagnosed covid-19 pneumonia. pharyngeal samples collected either at screening or within 7-days prior to screening for the same ongoing covid-19 pneumonia illness are acceptable 3. the patient requires, at baseline, high flow supplemental oxygen or positive pressure ventilation or is receiving oxygen via face mask, such as a non-rebreather or reservoir mask, capable of delivering high concentrations of oxygen 4. patient agrees to use appropriate methods of contraception during the study and 3 months after the last dose of study drug 5. the patient or legal representative has signed a written informed consent approved by the irb/ethics committee

inclusion criteria: 1. adult male or female ≥18 to ≤80 years of age 2. proven covid-19 infection per rt-pcr assay of a pharyngeal sample (nasopharyngeal or oropharyngeal) and pneumonia defined as radiographic opacities on chest x-ray or ct scan. that diagnosed covid-19 pneumonia. pharyngeal samples collected either at screening or within 7-days prior to screening for the same ongoing covid-19 pneumonia illness are acceptable 3. the patient requires, at baseline, high flow supplemental oxygen or positive pressure ventilation or is receiving oxygen via face mask, such as a non-rebreather or reservoir mask, capable of delivering high concentrations of oxygen 4. patient agrees to use appropriate methods of contraception during the study and 3 months after the last dose of study drug 5. the patient or legal representative has signed a written informed consent approved by the irb/ethics committee

inclusion criteria: adult male or female ≥18 to ≤80 years of age proven covid-19 infection per rt-pcr assay of a pharyngeal sample (nasopharyngeal or oropharyngeal) and pneumonia defined as radiographic opacities on chest x-ray or ct scan. that diagnosed covid-19 pneumonia. pharyngeal samples collected either at screening or within 7-days prior to screening for the same ongoing covid-19 pneumonia illness are acceptable the patient requires, at baseline, high flow supplemental oxygen or positive pressure ventilation or is receiving oxygen via face mask, such as a non-rebreather or reservoir mask, capable of delivering high concentrations of oxygen patient agrees to use appropriate methods of contraception during the study and 3 months after the last dose of study drug the patient or legal representative has signed a written informed consent approved by the irb/ethics committee

inclusion criteria: adult male or female ≥18 to ≤80 years of age proven covid-19 infection per rt-pcr assay of a pharyngeal sample (nasopharyngeal or oropharyngeal) and pneumonia defined as radiographic opacities on chest x-ray or ct scan. that diagnosed covid-19 pneumonia. pharyngeal samples collected either at screening or within 7-days prior to screening for the same ongoing covid-19 pneumonia illness are acceptable the patient requires, at baseline, high flow supplemental oxygen or positive pressure ventilation or is receiving oxygen via face mask, such as a non-rebreather or reservoir mask, capable of delivering high concentrations of oxygen patient agrees to use appropriate methods of contraception during the study and 3 months after the last dose of study drug the patient or legal representative has signed a written informed consent approved by the irb/ethics committee

inclusion criteria: 1. adult male or female ≥18 to ≤80 years of age 2. proven covid-19 infection per rt-pcr assay of a pharyngeal sample (nasopharyngeal or oropharyngeal) and pneumonia defined as radiographic opacities on chest x-ray or ct scan. that diagnosed covid-19 pneumonia. pharyngeal samples collected either at screening or within 7-days prior to screening for the same ongoing covid-19 pneumonia illness are acceptable 3. the patient requires, at baseline, high flow supplemental oxygen or positive pressure ventilation or is receiving oxygen via face mask, such as a non-rebreather or reservoir mask, capable of delivering high concentrations of oxygen 4. patient agrees to use appropriate methods of contraception during the study and 3 months after the last dose of study drug 5. the patient or legal representative has signed a written informed consent approved by the irb/ethics committee

inclusion criteria: 1. adult male or female ≥18 to ≤80 years of age 2. proven covid-19 infection per rt-pcr assay of a pharyngeal sample (nasopharyngeal or oropharyngeal) and pneumonia defined as radiographic opacities on chest x-ray or ct scan. that diagnosed covid-19 pneumonia. pharyngeal samples collected either at screening or within 7-days prior to screening for the same ongoing covid-19 pneumonia illness are acceptable 3. the patient requires, at baseline, high flow supplemental oxygen or positive pressure ventilation or is receiving oxygen via face mask, such as a non-rebreather or reservoir mask, capable of delivering high concentrations of oxygen 4. patient agrees to use appropriate methods of contraception during the study and 3 months after the last dose of study drug 5. the patient or legal representative has signed a written informed consent approved by the irb/ethics committee

inclusion criteria: 1. adult male or female ≥18 to ≤80 years of age 2. proven covid-19 infection per rt-pcr assay of a pharyngeal sample (nasopharyngeal or oropharyngeal) and pneumonia defined as radiographic opacities on chest x-ray or ct scan. that diagnosed covid-19 pneumonia. pharyngeal samples collected either at screening or within 7-days prior to screening for the same ongoing covid-19 pneumonia illness are acceptable 3. the patient requires, at baseline, high flow supplemental oxygen or positive pressure ventilation or is receiving oxygen via face mask, with an oxygen flow of >5l/min. 4. patient agrees to use appropriate methods of contraception during the study and 3 months after the last dose of study drug 5. the patient or legal representative has signed a written informed consent approved by the irb/ethics committee

inclusion criteria: 1. adult male or female ≥18 to ≤80 years of age 2. proven covid-19 infection per rt-pcr assay of a pharyngeal sample (nasopharyngeal or oropharyngeal) and pneumonia defined as radiographic opacities on chest x-ray or ct scan. that diagnosed covid-19 pneumonia. pharyngeal samples collected either at screening or within 7-days prior to screening for the same ongoing covid-19 pneumonia illness are acceptable 3. the patient requires, at baseline, high flow supplemental oxygen or positive pressure ventilation or is receiving oxygen via face mask, with an oxygen flow of >5l/min. 4. patient agrees to use appropriate methods of contraception during the study and 3 months after the last dose of study drug 5. the patient or legal representative has signed a written informed consent approved by the irb/ethics committee

inclusion criteria: 1. adult male or female ≥18 to ≤80 years of age 2. proven covid-19 infection per rt-pcr assay of a pharyngeal sample (nasopharyngeal or oropharyngeal) and pneumonia defined as radiographic opacities on chest x-ray or ct scan. that diagnosed covid-19 pneumonia. pharyngeal samples collected either at screening or within 7-days prior to screening for the same ongoing covid-19 pneumonia illness are acceptable 3. the patient requires, at baseline, high flow supplemental oxygen or cpap, if high oxygen flow is not an available option. 4. patient agrees to use appropriate methods of contraception during the study and 3 months after the last dose of study drug 5. the patient or legal representative has signed a written informed consent approved by the irb/ethics committee

inclusion criteria: 1. adult male or female ≥18 to ≤80 years of age 2. proven covid-19 infection per rt-pcr assay of a pharyngeal sample (nasopharyngeal or oropharyngeal) and pneumonia defined as radiographic opacities on chest x-ray or ct scan. that diagnosed covid-19 pneumonia. pharyngeal samples collected either at screening or within 7-days prior to screening for the same ongoing covid-19 pneumonia illness are acceptable 3. the patient requires, at baseline, high flow supplemental oxygen or cpap, if high oxygen flow is not an available option. 4. patient agrees to use appropriate methods of contraception during the study and 3 months after the last dose of study drug 5. the patient or legal representative has signed a written informed consent approved by the irb/ethics committee

inclusion criteria: 1. adult male or female ≥18 to ≤80 years of age 2. proven covid-19 infection per rt-pcr assay of a pharyngeal sample (nasopharyngeal or oropharyngeal) and pneumonia defined as radiographic opacities on chest x-ray or ct scan 3. the patient requires, at baseline, high flow supplemental oxygen or cpap, if high oxygen flow is not an available option. 4. patient agrees to use appropriate methods of contraception during the study and 3 months after the last dose of study drug 5. the patient or legal representative has signed a written informed consent approved by the irb/ethics committee

inclusion criteria: 1. adult male or female ≥18 to ≤80 years of age 2. proven covid-19 infection per rt-pcr assay of a pharyngeal sample (nasopharyngeal or oropharyngeal) and pneumonia defined as radiographic opacities on chest x-ray or ct scan 3. the patient requires, at baseline, high flow supplemental oxygen or cpap, if high oxygen flow is not an available option. 4. patient agrees to use appropriate methods of contraception during the study and 3 months after the last dose of study drug 5. the patient or legal representative has signed a written informed consent approved by the irb/ethics committee